Transcriptomics

Dataset Information

0

Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors


ABSTRACT: To clarigy the molecular mechanism underlying the IMiD-induced megakaryocytic lineage commitment in human megakaryocyte/erythrocyte progenitors, we performed transcriptome analysis of CD41-CD105+ and CD41+CD105- cells obtained from megakaryocyte/erythrocyte progenitors treated with lenalidomide for 72 hours. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. CD105-CD41+ cells showed the enrichment in the expression of genes related to megakaryocytes and platelet, whereas genes related to erythroid lineage were negatively enriched. CD41+CD105- cells expressed higher levels of transcription factors required for megakaryocyte differentiation including FLI1, RUNX1, and MEIS1. Furthermore, we performed a knockdown strategy with small interfering RNA against MEIS1 mRNA, confirming that lenalidomide-induced megakaryocyte commitment should be due to the up-regulation of MEIS1 in megakaryocyte/erythrocyte progenitors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE162212 | GEO | 2021/11/25

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2008-06-10 | GSE10593 | GEO
| PRJNA681011 | ENA
2010-06-26 | E-GEOD-10593 | biostudies-arrayexpress
2011-01-10 | GSE19901 | GEO
2011-01-10 | E-GEOD-19901 | biostudies-arrayexpress
2014-11-12 | GSE53263 | GEO
2012-05-20 | E-GEOD-37028 | biostudies-arrayexpress
2012-08-02 | E-GEOD-34543 | biostudies-arrayexpress
2020-11-18 | GSE158855 | GEO
2013-03-29 | E-GEOD-45619 | biostudies-arrayexpress